Skip to contentV
Valion Bio, Inc.
V
VBIOValion Bio, Inc. Q1 2024 · 10-Q
Revenue$334.00K$334.00K−11.2% vs Q1 2023 Net Income-$1.48M-$1.48MN/M vs Q1 2023 EPS Diluted-$17.15-$17.15N/M vs Q1 2023 Gross Profit$167,000+47.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
Operating Cash Flow-$1,666,000N/M Margins · derivedGross margin50.0%+19.9 pt vs Q1 2023
Operating margin-443.4%+119.4 pt vs Q1 2023
Net margin-443.4%+119.4 pt vs Q1 2023
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end